BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18444444)

  • 1. Patients with chronic pain on opioid therapy taking dronabinol: incidence of false negatives using radioimmunoassay.
    Narang S; Wasan AD; Ross EL; Michna E; Chen JY; Jamison RN
    J Opioid Manag; 2008; 4(1):21-6. PubMed ID: 18444444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
    Narang S; Gibson D; Wasan AD; Ross EL; Michna E; Nedeljkovic SS; Jamison RN
    J Pain; 2008 Mar; 9(3):254-64. PubMed ID: 18088560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
    Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
    Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
    ElSohly MA; deWit H; Wachtel SR; Feng S; Murphy TP
    J Anal Toxicol; 2001 Oct; 25(7):565-71. PubMed ID: 11599601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions.
    Naef M; Curatolo M; Petersen-Felix S; Arendt-Nielsen L; Zbinden A; Brenneisen R
    Pain; 2003 Sep; 105(1-2):79-88. PubMed ID: 14499423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Secondary Analysis from a Randomized Trial on the Effect of Plasma Tetrahydrocannabinol Levels on Pain Reduction in Painful Diabetic Peripheral Neuropathy.
    Wallace MS; Marcotte TD; Atkinson JH; Padovano HT; Bonn-Miller M
    J Pain; 2020; 21(11-12):1175-1186. PubMed ID: 32565122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability.
    de Vries M; Van Rijckevorsel DC; Vissers KC; Wilder-Smith OH; Van Goor H
    Br J Clin Pharmacol; 2016 Mar; 81(3):525-37. PubMed ID: 26505163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.
    Huestis MA; Elsohly M; Nebro W; Barnes A; Gustafson RA; Smith ML
    Ther Drug Monit; 2006 Aug; 28(4):540-4. PubMed ID: 16885722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study.
    de Vries M; van Rijckevorsel DCM; Vissers KCP; Wilder-Smith OHG; van Goor H;
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1079-1086.e4. PubMed ID: 27720917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.
    Issa MA; Narang S; Jamison RN; Michna E; Edwards RR; Penetar DM; Wasan AD
    Clin J Pain; 2014 Jun; 30(6):472-8. PubMed ID: 24281276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
    Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the impact of hemp food consumption on workplace drug tests.
    Leson G; Pless P; Grotenhermen F; Kalant H; ElSohly MA
    J Anal Toxicol; 2001; 25(8):691-8. PubMed ID: 11765026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
    Karst M; Salim K; Burstein S; Conrad I; Hoy L; Schneider U
    JAMA; 2003 Oct; 290(13):1757-62. PubMed ID: 14519710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model.
    Dunn KE; Bergeria CL; Huhn AS; Speed TJ; Mun CJ; Vandrey R; Campbell CM
    Neuropsychopharmacology; 2021 Jul; 46(8):1451-1459. PubMed ID: 33879842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 3H- and 125I-radioimmunoassay and gas chromatography/mass spectrometry for the determination of delta 9-tetrahydrocannabinol and cannabinoids in blood and serum.
    Hanson VW; Buonarati MH; Baselt RC; Wade NA; Yep C; Biasotti AA; Reeve VC; Wong AS; Orbanowsky MW
    J Anal Toxicol; 1983; 7(2):96-102. PubMed ID: 6304423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of delta-9-tetrahydrocannabinol (THC) in oral fluid, blood and urine following oral consumption of low-content THC hemp oil.
    Hayley AC; Downey LA; Hansen G; Dowell A; Savins D; Buchta R; Catubig R; Houlden R; Stough CKK
    Forensic Sci Int; 2018 Mar; 284():101-106. PubMed ID: 29408718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.
    Wachtel SR; ElSohly MA; Ross SA; Ambre J; de Wit H
    Psychopharmacology (Berl); 2002 Jun; 161(4):331-9. PubMed ID: 12073159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.